MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Amgen News Service' source. Thu, 09 Feb 2012 01:31:28 +0100 http://www.medworm.com/index.php?rid=5669451&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_discuss_application_for_new_use_of_xgeva_denosumab_at_fda_oncologi%2F THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today’s meeting of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5669451 Wed, 08 Feb 2012 05:00:00 +0100 5669451 http://www.medworm.com/index.php?rid=5631212&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_acquire_micromet%2F Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies Micromet’s Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types All-Cash Transaction Values Micromet at $1.16 Billion THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) and Micromet, Inc.  (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously approved by both the Amgen and Micromet Bo... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5631212 Thu, 26 Jan 2012 05:00:00 +0100 5631212 http://www.medworm.com/index.php?rid=5631211&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_full_year_2011_revenue_increased_4_percent_to_156_billion_and_adjust%2F Full Year 2011 GAAP EPS Decreased 16 Percent to $4.04 Due to a One-Time Charge 2012 Total Revenue and Adjusted EPS Expected to be in the Range of $16.1-$16.5 Billion and $5.90-$6.15, Respectively Amgen reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010.  For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5631211 Thu, 26 Jan 2012 05:00:00 +0100 5631211 http://www.medworm.com/index.php?rid=5631213&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2011_fourth_quarter_and_full_year_financial_resu%2F THOUSAND OAKS, Calif., Jan. 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Standard Time.  Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5631213 Tue, 24 Jan 2012 05:00:00 +0100 5631213 http://www.medworm.com/index.php?rid=5573535&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_30th_annual_jp_morgan_global_healthcare_conference%2F THOUSAND OAKS, Calif., Jan. 4, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012, at the Westin St. Francis in San Francisco, Calif.  Robert A. Bradway, president and chief operating officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5573535 Wed, 04 Jan 2012 05:00:00 +0100 5573535 http://www.medworm.com/index.php?rid=5573536&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_to_review_potential_new_use_of_xgeva_denosumab_at_oncologic_drugs_advis%2F THOUSAND OAKS, Calif., Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5573536 Thu, 29 Dec 2011 05:00:00 +0100 5573536 http://www.medworm.com/index.php?rid=5527942&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_watson_announce_collaboration_to_develop_and_commercialize_oncolo%2F THOUSAND OAKS, Calif. and PARSIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, infrastructure, and investment to ensure safe, reliably supplied therapies for patients. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5527942 Mon, 19 Dec 2011 05:00:00 +0100 5527942 http://www.medworm.com/index.php?rid=5507596&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_2012_first_quarter_dividend%2F THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the first quarter of 2012. This represents an approximate 29 percent increase from that paid in the previous two quarters. The dividend will be paid on March 7, 2012 to all stockholders of record as of the close of business on Feb. 15, 2012.  (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5507596 Thu, 15 Dec 2011 05:00:00 +0100 5507596 http://www.medworm.com/index.php?rid=5507595&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fkevin_sharer_amgen_chairman_and_ceo_announces_plan_to_retire_with_robert_br%2F Roger Perlmutter to Retire as EVP of Research and Development with Sean Harper to Assume the Role on February 13, 2012 THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/—Kevin W. Sharer, chairman and chief executive officer of Amgen (NASDAQ:AMGN) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen.  To facilitate an orderly transition process, Sharer will step down as CEO effective May 23, 2012, and remain as chairman of the Company’s Board of Directors until December 31, 2012, at which time he will retire from the Board and from the Company.  Robert Bradway, currently president and chief operating officer, will become CEO on May 23, 2012.  It is the intention of the Board of Directors to elect Bradway c... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5507595 Thu, 15 Dec 2011 05:00:00 +0100 5507595 http://www.medworm.com/index.php?rid=5507597&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_final_results_of_its_tender_offer%2F THOUSAND OAKS, Calif., Dec. 14, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5507597 Wed, 14 Dec 2011 05:00:00 +0100 5507597 http://www.medworm.com/index.php?rid=5507598&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_presents_final_results_from_the_largest_phase_3_open_label_study_asse%2F Additional Key Nplate Data Also Presented at American Society of Hematology Annual Meeting THOUSAND OAKS, Calif., Dec. 13, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) today announced that data from several key Nplate® (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 10-13, 2011, in San Diego. Of note, final results from the international, Phase 3, open-label, single-arm ‘209 study evaluating the safety and efficacy of Nplate in adults with primary immune thrombocytopenia (ITP) demonstrated that Nplate induced a rapid platelet response in adult ITP patients with low platelet counts or bleeding symptoms and maintained a consistent safety profile (Abstract No. 3279). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5507598 Tue, 13 Dec 2011 05:00:00 +0100 5507598 http://www.medworm.com/index.php?rid=5489227&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_22nd_annual_oppenheimer_healthcare_conference%2F THOUSAND OAKS, Calif., Dec. 9, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) will participate in the Oppenheimer Healthcare Conference on Wednesday, Dec. 14, 2011, at the Waldorf Astoria Hotel in New York City, beginning at 1:35 p.m.  Eastern Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5489227 Fri, 09 Dec 2011 05:00:00 +0100 5489227 http://www.medworm.com/index.php?rid=5489228&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_preliminary_results_of_its_tender_offer%2F THOUSAND OAKS, Calif., Dec. 8, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011. Based on the preliminary count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 98,062,630 shares of Amgen’s common stock were properly tendered and not properly withdrawn at or below the purchase price of $60.00 per share, including 30,827,827 shares that were tendered through notice of guaranteed delivery. Amgen has been informed by the depositary that the preliminary proration factor for the tender offer is approximately 85 percent. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5489228 Thu, 08 Dec 2011 05:00:00 +0100 5489228 http://www.medworm.com/index.php?rid=5479024&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_fda_agree_to_modify_nplate_romiplostim_risk_evaluation_and_mitiga%2F Prescribing Physicians, Patients and Institutions no Longer Required to Enroll in Nplate® NEXUS Program THOUSAND OAKS, Calif., Dec. 6, 2011 /PRNewswire/—Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribing physicians, patients and institutions are no longer required to enroll in the safety monitoring program, called the Nplate® NEXUS (Network of EXperts Understanding and Supporting Nplate and Patients) Program, in order to prescribe or receive Nplate. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5479024 Tue, 06 Dec 2011 05:00:00 +0100 5479024 http://www.medworm.com/index.php?rid=5443745&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fenbrel_etanercept_patent_issued%2F THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc.  ("Roche") and exclusively licensed to Amgen. Immunex Corporation (acquired by Amgen in 2002) originally licensed this patent application from Roche in 1999, and in 2004, Amgen paid Roche a one-time payment and obtained an exclusive, fully paid-up license to the application which issued today as the ‘182 patent. The patent describes and claims the fusion protein that is etanercept, and by statute, the ‘182 patent has a term of 17 years from today. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5443745 Tue, 22 Nov 2011 05:00:00 +0100 5443745 http://www.medworm.com/index.php?rid=5411945&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fvectibix_panitumumab_granted_approval_for_expanded_indications_in_the_europ%2F THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix® (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). This approval of Vectibix applies to all 27 European Union (EU) member states. Prior to this approval, Vectibix had received conditional approval in the EU as monotherapy. The monotherapy indication was also further revised to state that Vectibix is indicated for the treatment of pa... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5411945 Tue, 15 Nov 2011 05:00:00 +0100 5411945 http://www.medworm.com/index.php?rid=5411944&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fthe_lancet_publishes_results_demonstrating_xgeva_significantly_prolonged_bo%2F This study is the first to demonstrate that targeting the bone microenvironment prevents bone metastasis in men with prostate cancer. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5411944 Tue, 15 Nov 2011 05:00:00 +0100 5411944 http://www.medworm.com/index.php?rid=5411946&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_statement_on_european_investor_visit%2F THOUSAND OAKS, Calif., Nov. 14, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ:AMGN) today issued the following statement: Amgen will be meeting with investors in Europe this week with a view to raise $1-1.5 billion in Euro and Sterling denominated debt to support its share repurchase program, as well as for general corporate purposes. The timing of this potential offering will be subject to market conditions. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5411946 Mon, 14 Nov 2011 05:00:00 +0100 5411946 http://www.medworm.com/index.php?rid=5391458&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_plan_to_launch_tender_offer_and_launch_of_senior_notes_offe%2F THOUSAND OAKS, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock, par value $0.0001 per share ("Common Stock"). Amgen also announced a public offering of its senior notes, the proceeds of which will be used to fund the tender offer and for general corporate purposes. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5391458 Mon, 07 Nov 2011 05:00:00 +0100 5391458 http://www.medworm.com/index.php?rid=5391460&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fprolia_denosumab_open_label_extension_trial_showed_continued_increase_in_bo%2F THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial showing that six years of Prolia® (denosumab) treatment in postmenopausal women with osteoporosis was associated with continued increase in bone mineral density (BMD) and consistent reduction in markers of bone turnover. These results will be presented on Nov. 8, 2011, at the 2011 American College of Rheumatology Annual Scientific Meeting in Chicago. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5391460 Sat, 05 Nov 2011 04:00:00 +0100 5391460 http://www.medworm.com/index.php?rid=5391459&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ftreatment_with_enbrel_etanercept_shows_significant_and_sustained_clinical_b%2F Amgen and Pfizer Announce Results From the Largest Completed Clinical Trial of a Biologic Therapy in Adults with Moderately Active RA THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate (MTX) in Period one and were randomized to continue on ENBREL plus MTX or MTX alone in Period two. Results of Period two showed that the percentage of patients who maintained LDA or achieved clinical remission ... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5391459 Sat, 05 Nov 2011 04:00:00 +0100 5391459 http://www.medworm.com/index.php?rid=5350689&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_third_quarter_2011_revenue_and_adjusted_earnings_per_share_eps_each_%2F 2011 Total Revenue and Adjusted EPS Guidance Ranges Increased to $15.4-$15.6 Billion and $5.15-$5.30 Amgen’s Board of Directors Increased Stock Repurchase Authorization to $10 Billion Third Quarter 2011 GAAP EPS Were $0.50 as a Result of a Legal Settlement Reserve THOUSAND OAKS, Calif., Oct. 24, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the third quarter of 2011 to $3,944 million versus $3,816 million in the third quarter of 2010. Total product sales increased 3 percent in the third quarter of 2011 to $3,877 million versus $3,759 million in the third quarter of 2010. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5350689 Mon, 24 Oct 2011 04:00:00 +0100 5350689 http://www.medworm.com/index.php?rid=5339151&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_appoints_anthony_tony_hooper_executive_vice_president_global_commerci%2F THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer, and will be responsible for the Company’s Global Commercial Operations. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5339151 Wed, 19 Oct 2011 04:00:00 +0100 5339151 http://www.medworm.com/index.php?rid=5339150&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2011_third_quarter_financial_results%2F THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Monday, Oct. 24, 2011 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m.  Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5339150 Wed, 19 Oct 2011 04:00:00 +0100 5339150 http://www.medworm.com/index.php?rid=5317604&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_2011_fourth_quarter_dividend%2F THOUSAND OAKS, Calif., Oct. 13, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.28 per share dividend for the fourth quarter of 2011.  The dividend will be paid on Dec. 8, 2011 to all stockholders of record as of the close of business on Nov.  17, 2011. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5317604 Thu, 13 Oct 2011 04:00:00 +0100 5317604 http://www.medworm.com/index.php?rid=5317603&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_appoints_robert_a_bradway_to_the_companys_board_of_directors%2F THOUSAND OAKS, Calif., Oct. 13, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced today that its Board of Directors has appointed Robert A. Bradway to the Company’s Board. Bradway, 48, is Amgen’s president and chief operating officer. The addition of Bradway brings the number of Amgen board members to 13. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5317603 Thu, 13 Oct 2011 04:00:00 +0100 5317603 http://www.medworm.com/index.php?rid=5253357&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_data_to_be_presented_at_2011_european_multidisciplinary_ca%2F THOUSAND OAKS, Calif., Sept. 23, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5253357 Fri, 23 Sep 2011 04:00:00 +0100 5253357 http://www.medworm.com/index.php?rid=5241299&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_approves_new_indications_for_prolia_denosumab_for_the_treatment_of_bone%2F Prolia is the First-and-Only Medicine Approved for Cancer Treatment-Induced Bone Loss THOUSAND OAKS, Calif., Sept. 19, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer. In patients with prostate cancer, Prolia also reduced the incidence of vertebral fractures.  Prolia is the first-and-only therapy approved by the FDA for cancer treatment-induced bone loss in patients undergoing hormone... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5241299 Mon, 19 Sep 2011 04:00:00 +0100 5241299 http://www.medworm.com/index.php?rid=5241300&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fprolia_denosumab_phase_2_extension_study_showed_continued_increase_in_bone_%2F THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover. The data were presented at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5241300 Sat, 17 Sep 2011 04:00:00 +0100 5241300 http://www.medworm.com/index.php?rid=5229050&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_staff_volunteer_efforts_result_in_5000_for_each_of_their_favorite_non%2F THOUSAND OAKS, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/—Each year, thousands of Amgen staff generously devote their personal time, energy and talents to a variety of charitable organizations. To recognize these exceptional efforts, the Amgen Foundation today announced the 11 recipients of the 2011 Amgen Excellence in Volunteering Awards. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5229050 Thu, 15 Sep 2011 04:00:00 +0100 5229050 http://www.medworm.com/index.php?rid=5229049&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_ubs_global_life_sciences_conference1%2F THOUSAND OAKS, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, Sept. 20, 2011, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5229049 Thu, 15 Sep 2011 04:00:00 +0100 5229049 http://www.medworm.com/index.php?rid=5212895&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_morgan_stanley_global_healthcare_conference%2F THOUSAND OAKS, Calif., Sept. 8, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 13, 2011 at the Grand Hyatt in New York City, beginning at 9:10 a.m. Eastern Time. Jim Daly, senior vice president of North America Commercial Operations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5212895 Thu, 08 Sep 2011 04:00:00 +0100 5212895 http://www.medworm.com/index.php?rid=5198715&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_baird_healthcare_conference1%2F THOUSAND OAKS, Calif., Sept. 6, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 8, 2011, at The New York Palace Hotel in New York City, beginning at 10:00 a.m. Eastern Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5198715 Mon, 05 Sep 2011 23:00:00 +0100 5198715 http://www.medworm.com/index.php?rid=5186704&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_stifel_nicolaus_healthcare_conference%2F THOUSAND OAKS, Calif., Sept. 2, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) will present at the Stifel Nicolaus Healthcare Conference on Wednesday, Sept. 7, 2011 at the Four Seasons Hotel, Boston, Mass., beginning at 8:35 a.m. Eastern Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5186704 Thu, 01 Sep 2011 23:00:00 +0100 5186704 http://www.medworm.com/index.php?rid=5165219&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Faward_winning_actress_blythe_danner_and_amgen_launch_act_2_reduce_fractures%2F Campaign Educates and Encourages Women With Postmenopausal Osteoporosis at Increased Risk for Fractures to Take Action to Help Strengthen Their Bones THOUSAND OAKS, Calif., Aug. 25, 2011 /PRNewswire via COMTEX/ -- Emmy® and Tony® award-winning actress Blythe Danner and Amgen (NASDAQ:AMGN) today launch Act 2 Reduce Fractures™, an educational campaign for women with postmenopausal osteoporosis at increased risk for fractures. Earlier this year, Danner was diagnosed with postmenopausal osteoporosis at increased risk for fractures and wants to encourage women like her to educate themselves, take action and speak to their doctors to learn all they can about helping to strengthen their bones. The campaign is being supported by American Bone Health, the Global Healthy Living Foundation and... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5165219 Wed, 24 Aug 2011 23:00:00 +0100 5165219 http://www.medworm.com/index.php?rid=5149523&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_pdufa_date_for_xgeva_supplemental_biologics_license_applica%2F THOUSAND OAKS, Calif., Aug. 22, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) will target a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. Bone is one of the most common places for cancer to spread. If approved in this expanded indication, XGEVA would become the first therapy licensed to prevent or delay the spread of cancer to bone. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5149523 Sun, 21 Aug 2011 23:00:00 +0100 5149523 http://www.medworm.com/index.php?rid=5149524&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_data_to_be_presented_at_american_society_for_bone_and_mine%2F THOUSAND OAKS, Calif., Aug. 18, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif.  from Sept. 16-20, 2011. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5149524 Wed, 17 Aug 2011 23:00:00 +0100 5149524 http://www.medworm.com/index.php?rid=5072714&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_second_quarter_2011_revenue_increased_4_percent_to_40_billion%2F Second Quarter 2011 Product Sales Increased 8 Percent to $3.9 Billion Second Quarter 2011 Adjusted and GAAP Earnings Per Share (EPS) Were $1.37 and $1.25, Respectively Amgen Announced its First Quarterly Cash Dividend of $0.28 Per Share 2011 Total Revenue and Adjusted EPS Guidance Updated to Upper End of $15.1 Billion to $15.5 Billion and $5.00 to $5.20, Respectively THOUSAND OAKS, Calif., July 29, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quart... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5072714 Thu, 28 Jul 2011 23:00:00 +0100 5072714 http://www.medworm.com/index.php?rid=5065575&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2011_second_quarter_financial_results%2F THOUSAND OAKS, Calif., July 25, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that it will report its second quarter financial results on Friday, July 29, 2011 before the opening of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 8 a.m.  Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5065575 Sun, 24 Jul 2011 23:00:00 +0100 5065575 http://www.medworm.com/index.php?rid=5043455&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fxgeva_denosumab_granted_marketing_authorization_in_the_european_union%2F Additional Year of Market Exclusivity Granted Based on Significant Clinical Benefit XGEVA Provides Over Existing Therapies THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA an additional year of data and market exclusivity in the EU since the indication was considered new for denosumab and based on the significant clinical benefit of XGEVA in comparison with exi... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5043455 Thu, 14 Jul 2011 23:00:00 +0100 5043455 http://www.medworm.com/index.php?rid=5043454&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_resolves_g_csf_patent_litigation_with_teva%2F Teva Admits Neutroval(TM) Infringes Amgen’s Valid and Enforceable Patents Court Enters Permanent Injunction THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced today that the United States (U.S.) District Court in Pennsylvania has entered final judgment and a permanent injunction against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA prohibiting them from infringing Amgen’s patents relating to human G-CSF (granulocyte colony-stimulating factor) and methods for its use. Today’s judgment was accompanied by Teva’s admission that its Neutroval(TM) product infringes the two Amgen patents at issue in the litigation and that those patents are valid and enforceable. The Court’s injunction extends until Nov.  10, 2013, af... Amgen News Service news http://www.medworm.com/rss/comments.php?id=5043454 Thu, 14 Jul 2011 23:00:00 +0100 5043454 http://www.medworm.com/index.php?rid=5043456&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_ucb_team_up_with_nasa_on_final_space_shuttle_mission_to_conduct_p%2F Thousand Oaks, Calif. and BRUSSELS, July 5, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today that they are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis, on the final NASA shuttle mission, Space Shuttle Flight STS-135, scheduled to launch July 8, 2011. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=5043456 Mon, 04 Jul 2011 23:00:00 +0100 5043456 http://www.medworm.com/index.php?rid=4979214&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_submits_application_to_expand_indication_for_xgeva_denosumab_to_preve%2F THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4979214 Sun, 26 Jun 2011 23:00:00 +0100 4979214 http://www.medworm.com/index.php?rid=4963700&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_receives_positive_chmp_opinion_for_vectibix_panitumumab_in_combinatio%2F THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Vectibix® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for patients with wild-type KRAS metastatic colorectal cancer (mCRC), following a successful re-examination procedure by Amgen. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4963700 Thu, 23 Jun 2011 23:00:00 +0100 4963700 http://www.medworm.com/index.php?rid=4963699&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_modifications_to_us_prescribing_information_for_use_of_eryt%2F Modified Labeling Provides Different Treatment Guidance for Patients on Dialysis and Not on Dialysis Changes to Prescribing Information Include Modification to the Boxed Warning THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved modified language in the prescribing information for the use of erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), in patients with chronic kidney disease (CKD). The modified language, including changes to the Boxed Warning, provides important new information for the treatment of patients with CKD who are on dialysis, as well as those not on dialysis, to inform prescribers and patients of safety ri... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4963699 Thu, 23 Jun 2011 23:00:00 +0100 4963699 http://www.medworm.com/index.php?rid=4963698&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnotice_to_investors_regarding_2011_and_2015_guidance%2F THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire via COMTEX/—Today, Amgen (NASDAQ: AMGN) issued the following notice to investors: Amgen reaffirms its guidance for 2011 and 2015. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4963698 Thu, 23 Jun 2011 23:00:00 +0100 4963698 http://www.medworm.com/index.php?rid=4963701&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fteachers_and_schools_across_north_america_receive_10000_amgen_award_for_sci%2F THOUSAND OAKS, Calif., June 21, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced the 34 science teachers in the United States, Canada and Puerto Rico who are this year’s recipients of the 19th annual Amgen Award for Science Teaching Excellence. The award recognizes extraordinary science teachers at the kindergarten through 12th grade level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4963701 Mon, 20 Jun 2011 23:00:00 +0100 4963701 http://www.medworm.com/index.php?rid=4963702&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdata_presented_at_two_global_medical_congresses_reinforce_benefit_of_enbrel%2F New Interim Results from the PRESERVE Study Evaluate ENBREL Therapy in Patients with Moderately Active Rheumatoid Arthritis Analysis of Ankylosing Spondylitis Trials Suggests Nocturnal Back Pain is Predictive of Fatigue, and ENBREL was Shown to Reduce These Symptoms PRISTINE Trial Data Explore Effects of ENBREL on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, inclu... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4963702 Tue, 24 May 2011 23:00:00 +0100 4963702 http://www.medworm.com/index.php?rid=4849312&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_receives_chmp_positive_opinion_for_xgeva_denosumab_in_the_european_un%2F Positive Opinion Based on Largest Clinical Program Ever Conducted in Patients with Bone Metastases THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA™ (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. If approved by the European Commission, Amgen would receive marketing authorization for XGEVA in all European Union (EU) Member States. The CHMP also recommended to grant XGEVA an additional year of data and market exclusivity... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4849312 Thu, 19 May 2011 23:00:00 +0100 4849312 http://www.medworm.com/index.php?rid=4849311&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_voting_results_of_annual_meeting_of_stockholders2%2F SEATTLE, May 20, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN), today announced results of voting at the Company’s Annual Meeting of Stockholders, held at The Fairmont Olympic Hotel in Seattle, Wash. Approximately 86.32 percent of outstanding shares were represented at the meeting. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4849311 Thu, 19 May 2011 23:00:00 +0100 4849311 http://www.medworm.com/index.php?rid=4835264&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_oncology_data_to_be_presented_at_asco_annual_meeting%2F THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago. These studies include data from the XGEVA® (denosumab), Vectibix® (panitumumab), ganitumab (AMG 479) and AMG 386 programs. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4835264 Tue, 17 May 2011 23:00:00 +0100 4835264 http://www.medworm.com/index.php?rid=4835265&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fphase_3_data_demonstrate_xgeva_denosumab_is_first_bone_targeted_therapy_to_%2F Study Meets Primary Endpoint by Significantly Improving Bone Metastasis-Free Survival for More Than Four Months Up to 90 Percent of Men with Advanced Prostate Cancer Will Develop Bone Metastases THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial (’147) demonstrating that XGEVA™ (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.  Full results of the ‘147 study were presented for the first time today in a late-breaking plenary session at the American Urological Association (AUA) 2011 Annual Meeting in Washington, D.C. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4835265 Mon, 16 May 2011 23:00:00 +0100 4835265 http://www.medworm.com/index.php?rid=4823895&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_webcast_investor_meeting_at_upcoming_american_urological_associati%2F THOUSAND OAKS, Calif., May 13, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) will webcast its investor meeting at the upcoming American Urological Association (AUA) Conference on Tuesday, May 17 at 12:00 p.m. Eastern Time. Members of Amgen’s scientific and management team and a clinical investigator will participate at the meeting to discuss data being presented at AUA. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4823895 Thu, 12 May 2011 23:00:00 +0100 4823895 http://www.medworm.com/index.php?rid=4808319&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fpatrick_dempsey_teams_up_with_breakaway_from_cancer_to_help_connect_cancer_%2F THOUSAND OAKS, Calif., May 11, 2011 /PRNewswire via COMTEX/—Patrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen’s Breakaway from Cancer® initiative. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4808319 Tue, 10 May 2011 23:00:00 +0100 4808319 http://www.medworm.com/index.php?rid=4808320&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffive_californians_selected_as_breakaway_from_cancer_champions_to_be_honored%2F Amgen’s Breakaway from Cancer to Honor and Celebrate Cancer Survivors at Every Stage of the Sixth Annual Race THOUSAND OAKS, Calif., May 10, 2011 /PRNewswire via COMTEX/—Amgen today announced that five inspirational cancer survivors who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer Champions as part of Amgen’s Breakaway from Cancer initiative. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4808320 Mon, 09 May 2011 23:00:00 +0100 4808320 http://www.medworm.com/index.php?rid=4765232&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_deutsche_bank_36th_annual_healthcare_conference%2F THOUSAND OAKS, Calif., April 28, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will present at the Deutsche Bank 36th Annual Healthcare Conference on Tuesday, May 3, 2011 at the InterContinental, Boston, Mass., beginning at 9:20 a.m. Eastern Time. Senior Vice President of North America Commercial Operations Jim Daly will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4765232 Thu, 28 Apr 2011 23:00:00 +0100 4765232 http://www.medworm.com/index.php?rid=4738089&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_ucb_announce_positive_phase_2_results_of_amg_785_cdp7851_in_patie%2F Top-line Results Met Primary Endpoint THOUSAND OAKS, Calif. and BRUSSELS, April 21, 2011 /PRNewswire via COMTEX/ —Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4738089 Wed, 20 Apr 2011 23:00:00 +0100 4738089 http://www.medworm.com/index.php?rid=4738088&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_outlines_strategy_growth_objectives_and_capital_allocation_plans%2F Company Provides Guidance For 2015 Announces Quarterly Dividend Policy NEW YORK, April 21, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today outlined the Company’s strategy, capital allocation plans and provided financial guidance for 2015 during a meeting with investors in New York. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4738088 Wed, 20 Apr 2011 23:00:00 +0100 4738088 http://www.medworm.com/index.php?rid=4738090&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_first_quarter_2011_revenue_increased_3_percent_to_37_billion%2F First Quarter 2011 Adjusted Earnings Per Share Increased 3 Percent To $1.34 First Quarter 2011 GAAP Earnings Per Share Increased 2 Percent To $1.20 THOUSAND OAKS, Calif., April 20, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS) of $1.34 for the first quarter of 2011, an increase of 3 percent compared to $1.30 for the first quarter of 2010. Adjusted net income decreased 2 percent to $1,258 million in the first quarter of 2011 compared to $1,282 million in the first quarter of 2010. Total revenue increased 3 percent during the first quarter of 2011 to $3,706 million versus $3,592 million in the first quarter of 2010. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4738090 Tue, 19 Apr 2011 23:00:00 +0100 4738090 http://www.medworm.com/index.php?rid=4716725&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_webcast_2011_business_review_meeting_on_april_21%2F THOUSAND OAKS, Calif., April 14, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Thursday, April 21, 2011 at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Time. In the meeting, Kevin Sharer, chairman and CEO, Robert A. Bradway, president and COO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, and Jonathan M. Peacock, executive vice president and CFO, will discuss the Company’s strategy and long-term growth objectives, commercial performance and expectations, research and development innovation and pipeline progress, financial performance expectations and the Company’s capital allocation plan. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4716725 Wed, 13 Apr 2011 23:00:00 +0100 4716725 http://www.medworm.com/index.php?rid=4711571&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2011_first_quarter_financial_results%2F THOUSAND OAKS, Calif., April 13, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced that it plans to report its first quarter financial results on Wednesday, April 20, 2011 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4711571 Tue, 12 Apr 2011 23:00:00 +0100 4711571 http://www.medworm.com/index.php?rid=4689037&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_establishes_commercial_operations_in_brazil%2F Amgen Acquires Privately Held Brazilian Pharmaceutical Company Bergamo and Agrees to Reacquire Rights to Certain Amgen Products in Brazil from Hypermarcas THOUSAND OAKS, Calif., April 8, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN), the world’s largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company. Amgen has also agreed to reacquire rights in Brazil to its products that were previously granted to Mantecorp (subsequently acquired by Hypermarcas). Together, these transactions will provide Amgen a significant presence in Brazil and immediate, direct access to one of the fastest growing pharmaceutical markets in the world. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4689037 Thu, 07 Apr 2011 23:00:00 +0100 4689037 http://www.medworm.com/index.php?rid=4660671&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ftop_line_results_announced_of_pivotal_phase_3_motesanib_trial_in_advanced_n%2F THOUSAND OAKS, Calif., CAMBRIDGE, Mass. and OSAKA, Japan, March 30, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival (OS) (hazard ratio 0.90, 95 percent CI 0.78 - 1.04, p=0.14). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4660671 Tue, 29 Mar 2011 23:00:00 +0100 4660671 http://www.medworm.com/index.php?rid=4660670&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_appeal_chmp_opinion_on_vectibix_panitumumab_use_with_chemotherapy_%2F THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP)for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4660670 Tue, 29 Mar 2011 23:00:00 +0100 4660670 http://www.medworm.com/index.php?rid=4660673&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fprolia_denosumab_open_label_extension_trial_showed_continued_increase_in_bo%2F THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the fourth and fifth years of consecutive Prolia treatment. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4660673 Wed, 23 Mar 2011 00:00:00 +0100 4660673 http://www.medworm.com/index.php?rid=4660672&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ftreatment_with_prolia_denosumab_associated_with_significantly_greater_adher%2F New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4660672 Wed, 23 Mar 2011 00:00:00 +0100 4660672 http://www.medworm.com/index.php?rid=4365766&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fboehringer_ingelheim_to_purchase_amgens_fremont_california_facility%2F Boehringer Ingelheim to Strengthen Global Biopharma Presence and Amgen to Maintain Strong Presence in San Francisco Bay Area Biotech Hub THOUSAND OAKS, Calif. and INGELHEIM, Germany, Jan. 18, 2011 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen’s rights in and substantially all assets at Amgen’s Fremont California development and manufacturing facility. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4365766 Tue, 18 Jan 2011 00:00:00 +0100 4365766 http://www.medworm.com/index.php?rid=4323429&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fsensipar_patents_upheld_by_district_court%2F Injunction Prohibits Teva and Barr from Marketing Generic Versions of Amgen’s Sensipar Through 2018 Patent Expiry THOUSAND OAKS, Calif., Jan. 7, 2011 /PRNewswire via COMTEX/—A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen’s (Nasdaq: AMGN) Sensipar® (cinacalcet) until expiration of the drug’s U.S. patents. The latest Sensipar expiry is in 2018.  Sensipar is approved for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for the treatment of elevated levels of calcium in patients with parathyroid carcinoma. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4323429 Fri, 07 Jan 2011 00:00:00 +0100 4323429 http://www.medworm.com/index.php?rid=4323431&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_xencor_enter_option_deal_to_co_develop_xencors_novel_antibody_for%2F THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(R)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4323431 Thu, 06 Jan 2011 00:00:00 +0100 4323431 http://www.medworm.com/index.php?rid=4323430&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_29th_annual_jp_morgan_healthcare_conference%2F THOUSAND OAKS, Calif., Jan. 6, 2011 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will present at the 29th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 11, 2011, at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4323430 Thu, 06 Jan 2011 00:00:00 +0100 4323430 http://www.medworm.com/index.php?rid=4269443&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fteach_for_america_and_the_amgen_foundation_renew_partnership_to_improve_mat%2F $1.8 Million Grant Will Enable Teach For America to Recruit and Train More Math and Science Graduates to Join the Teaching Corps THOUSAND OAKS, Calif. and NEW YORK, Dec. 16, 2010 /PRNewswire via COMTEX/—Teach For America and the Amgen Foundation today announced the renewal of their partnership to advance math and science education in America’s underserved public schools. Under this partnership, the Amgen Foundation pledged $1.8 million to increase the number of outstanding math and science graduates who join Teach For America’s teaching corps by 2013. This new grant brings the total support from Amgen Foundation to more than $7 million since 2004. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4269443 Thu, 16 Dec 2010 00:00:00 +0100 4269443 http://www.medworm.com/index.php?rid=4255795&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fxgeva_denosumab_significantly_improved_bone_metastasis_free_survival_in_men%2F Pivotal Phase 3 ‘147 Study Meets Primary Endpoint First Bone-Targeted Therapy to Delay the Onset of Bone Metastases in Patients with Prostate Cancer THOUSAND OAKS, Calif., Dec. 13, 3010, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the ‘147 study, demonstrated that XGEVA significantly improved median bone metastasis-free survival by 4.2 months (HR=0.85, 95 percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), and significantly improved time to first occurrence of bone metastases (secondary endpoint). Overall survival was similar between the XGEVA and placebo groups (secondary endpoint). (S... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4255795 Mon, 13 Dec 2010 00:00:00 +0100 4255795 http://www.medworm.com/index.php?rid=4250390&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_presents_new_xgeva_denosumab_breast_cancer_skeletal_related_event_pre%2F XGEVA Long Term Extension Data Demonstrate XGEVA Delayed Skeletal-Related Events by Five Months Compared to Zometa® Additional Data Shows Advanced Breast Cancer Patients Treated with XGEVA Experienced Less Disruption of Daily Functioning from Pain and Improvements in Health-Related Quality of Life THOUSAND OAKS, Calif., Dec. 10, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA™ (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa(R) (zoledronic acid). These results underscore the efficacy profile of XGEVA in preventing skeletal-related events (SREs) in patients with bone metastases from advanced breast cancer, as well as explo... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4250390 Fri, 10 Dec 2010 00:00:00 +0100 4250390 http://www.medworm.com/index.php?rid=4243609&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fthree_innovative_ideas_receive_10000_prizes_in_patients_choices_empowerment%2F THOUSAND OAKS, Calif. and WASHINGTON, Dec. 8, 2010 /PRNewswire via COMTEX/ —The Amgen Foundation and Ashoka’s Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for their innovative solutions that empower and elevate patients’ voices to improve health outcomes. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4243609 Wed, 08 Dec 2010 00:00:00 +0100 4243609 http://www.medworm.com/index.php?rid=4243608&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_deutsche_banks_2010_biofest%2F THOUSAND OAKS, Calif., Dec. 8, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will participate in Deutsche Bank’s 2010 BioFEST on Wednesday, Dec. 15, 2010, at the Four Seasons in Boston, beginning at 10:00 a.m.  Eastern Time. Roy Baynes, M.D., Ph.D., vice president of Global Development and Arvind Sood, vice president, Investor Relations will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4243608 Wed, 08 Dec 2010 00:00:00 +0100 4243608 http://www.medworm.com/index.php?rid=4243610&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_nplate_maintains_platelet_counts_for_more_than_five_years_in_adults_%2F Final Results From Largest And Longest Study To Date Evaluating Exposure To A Platelet Producer Presented At ASH ORLANDO, Fla., Dec. 5, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The complete data, presented as an oral presentation at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), demonstrated that Nplate safely and effectively maintained platelet counts in the signif... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4243610 Sun, 05 Dec 2010 00:00:00 +0100 4243610 http://www.medworm.com/index.php?rid=4222753&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_data_to_be_presented_at_american_society_of_hematology_ann%2F Final Results From The Largest And Longest Study Of Nplate® For The Treatment Of Adult Chronic ITP To Be Presented Amgen Expands Amgen FIRST STEP™ Program Co-Pay Coupon Benefits To Help Patients With Out-of-Pocket Costs For Neulasta® And Nplate® THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.  Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of Nplate in this setting, including the final efficacy and sa... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4222753 Thu, 02 Dec 2010 00:00:00 +0100 4222753 http://www.medworm.com/index.php?rid=4180857&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_approves_amgens_xgevatm_denosumab_for_the_prevention_of_skeletal_relate%2F First Bone Targeted Therapy for Cancer Patients to Be Approved in Nearly a Decade Approval Based on Largest Clinical Program Ever Conducted in Patients with Bone Metastases THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA(TM) (denosumab), the first and only RANK Ligand inhibitorfor the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a 6 month priority review by the FDA, a designation reserved for drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. (Source: ... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4180857 Thu, 18 Nov 2010 00:00:00 +0100 4180857 http://www.medworm.com/index.php?rid=4177153&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_foundation_and_ashokas_changemakers_announce_finalists_in_patients_ch%2F Voting Starts Today THOUSAND OAKS, Calif. and WASHINGTON, Nov. 17, 2010 /PRNewswire via COMTEX/ —The Amgen Foundation and Ashoka’s Changemakers today announced ten finalists in the Patients | Choices | Empowerment competition and launched public online voting in search of the best innovative solutions that empower patients, elevate patients’ voices, and improve health outcomes. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4177153 Wed, 17 Nov 2010 00:00:00 +0100 4177153 http://www.medworm.com/index.php?rid=4177154&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fcall_for_applications_the_amgen_award_for_science_teaching_excellence2%2F 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates THOUSAND OAKS, Calif., Nov. 16, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4177154 Tue, 16 Nov 2010 00:00:00 +0100 4177154 http://www.medworm.com/index.php?rid=4156964&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_foundation_recognizes_outstanding_staff_volunteers_and_contributes_55%2F THOUSAND OAKS, Calif., Nov. 11, 2010 /PRNewswire via COMTEX/—Amgen today announced the 11 recipients of the Amgen Excellence in Volunteering Awards. Launched this year by the Amgen Foundation, the Awards recognize staff in the United States (U.S.) and Puerto Rico who are making a difference in the communities where the company has a presence. The Amgen Foundation will award $5,000 to each nonprofit organization featured in the winning staff members’ applications. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4156964 Thu, 11 Nov 2010 00:00:00 +0100 4156964 http://www.medworm.com/index.php?rid=4153748&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_scholars_undergraduate_summer_research_program_begins_phase_2%2F Eight-Year, $34 Million Program, in Partnership with 13 Top Universities, Will Reach Nearly 2,500 Undergraduates THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire via COMTEX/—Today, Amgen Scholars, the signature initiative of the Amgen Foundation, moves into its second phase of what has become a $34 million program to advance science learning and inspire the next generation of scientists. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4153748 Wed, 10 Nov 2010 00:00:00 +0100 4153748 http://www.medworm.com/index.php?rid=4153747&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fstudy_published_in_new_england_journal_of_medicine_shows_nplater_significan%2F THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients. Data also showed that patients receiving SOC therapies required splenectomies earlier when compared with patients treated with Nplate. Additionally, patients in the Nplate group experienced increased platelet counts, higher platelet response rates, less bleed... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4153747 Wed, 10 Nov 2010 00:00:00 +0100 4153747 http://www.medworm.com/index.php?rid=4146779&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_19th_annual_credit_suisse_healthcare_conference%2F THOUSAND OAKS, Calif., Nov. 9, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will participate in the 19th Annual Credit Suisse Healthcare Conference on Friday, Nov. 12, 2010, at the Biltmore Hotel in Phoenix, Ariz., beginning at 8:30 a.m. Mountain Time. Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4146779 Tue, 09 Nov 2010 00:00:00 +0100 4146779 http://www.medworm.com/index.php?rid=4146780&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fpublished_results_show_denosumab_superior_to_zometar_in_delaying_or_prevent%2F Bone is One of the Most Common Sites for Distant Metastases Affecting up to 75 percent of Patients with Advanced Breast Cance THOUSAND OAKS, Calif., Nov. 8, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. An SRE consists of any of the following: a pathologic fracture, the need for radiation or surgery to ameliorate bone pathology secondary to tumor growth, or spinal cord compression. The study, published today in the Journal of Clinical Oncology, found that denosumab was superior to Zometa in delaying or preventing SREs in breast cancer p... Amgen News Service news http://www.medworm.com/rss/comments.php?id=4146780 Mon, 08 Nov 2010 00:00:00 +0100 4146780 http://www.medworm.com/index.php?rid=4146781&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_pfizer_and_world_class_professional_golfer_phil_mickelson_announce_pa%2F Collaboration Aims to Empower Patients with Psoriatic Arthritis and Rheumatoid Arthritis to Seek Care THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil’s experience with his diagnosis of psoriatic arthritis and treatment with Enbrel® (etanercept), and to encourage patients with similar symptoms to visit their doctor for proper assessment and care. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4146781 Sat, 06 Nov 2010 00:00:00 +0100 4146781 http://www.medworm.com/index.php?rid=4137041&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fprolia_denosumab_receives_best_new_drug_honor_at_scrip_awards%2F THOUSAND OAKS, Calif., Nov. 5, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug awardfor Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME’s Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4137041 Fri, 05 Nov 2010 00:00:00 +0100 4137041 http://www.medworm.com/index.php?rid=4129352&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fcompany_urges_fda_to_put_patients_first_as_regulators_implement_biosimilar_%2F THOUSAND OAKS, Calif., Nov. 1, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.  (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4129352 Mon, 01 Nov 2010 00:00:00 +0100 4129352 http://www.medworm.com/index.php?rid=4102765&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_third_quarter_2010_revenue_unchanged_at_38_billion_versus_prior_year%2F Third Quarter 2010 Adjusted Earnings Per Share Decreased 9 Percent to $1.36 Third Quarter 2010 GAAP Earnings Per Share Decreased 6 Percent to $1.28 2010 Revenue and Adjusted EPS Guidance Reaffirmed THOUSAND OAKS, Calif., Oct 25, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009.  (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4102765 Sun, 24 Oct 2010 23:00:00 +0100 4102765 http://www.medworm.com/index.php?rid=4092551&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2010_third_quarter_financial_results%2F THOUSAND OAKS, Calif., Oct 20, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Monday, Oct. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4092551 Tue, 19 Oct 2010 23:00:00 +0100 4092551 http://www.medworm.com/index.php?rid=4092550&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fbreakaway_from_cancerr_launches_striking_the_balance_podcast_series_to_insp%2F THOUSAND OAKS, Calif., Oct 20, 2010 /PRNewswire via COMTEX/—Amgen announced today the launch of the Breakaway from Cancer(R) initiative’s "Striking the Balance" podcast series. The series presents the best moments from a dynamic, first-of-its-kind roundtable event held with Amgen’s four nonprofit Breakaway from Cancer partner organizations at the 2010 American Society of Clinical Oncology (ASCO) annual meeting. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4092550 Tue, 19 Oct 2010 23:00:00 +0100 4092550 http://www.medworm.com/index.php?rid=4092552&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_review_results_from_treat_and_propose_updates_to_esa_labeling_for_%2F THOUSAND OAKS, Calif., Oct 18, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today’s meeting of the Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=4092552 Sun, 17 Oct 2010 23:00:00 +0100 4092552 http://www.medworm.com/index.php?rid=3800912&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_second_quarter_2010_adjusted_earnings_per_share_increased_7_percent_%2F Second Quarter 2010 Revenue Increased 2 Percent to $3.8 Billion Second Quarter 2010 GAAP Earnings Per Share Unchanged at $1.25 Adjusting for the Impact of a Weaker Euro, 2010 Total Revenue Guidance Revised to Slightly Below $15.1 Billion 2010 Adjusted Earnings Per Share Guidance Unchanged at Towards Lower End of $5.05-$5.25 THOUSAND OAKS, Calif., July 29, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.38 for the second quarter of 2010, an increase of 7 percent compared to $1.29 for the second quarter of 2009. Adjusted net income increased 1 percent to $1,326 million for the second quarter of 2010 compared to $1,311 million for the second quarter of 2009. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3800912 Wed, 28 Jul 2010 23:00:00 +0100 3800912 http://www.medworm.com/index.php?rid=3800913&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2F2010_addressing_psoriasis_contest_winners_attend_a_style_consultation_with_%2F Five Winners with Moderate to Severe Plaque Psoriasis Receive Individualized Advice to Help Achieve Their Best Personal Style NEW YORK, July 28, 2010 /PRNewswire via COMTEX/—Amgen and Pfizer today announced the five winners of the 2010 Addressing Psoriasis™ contest, which recognizes people with moderate to severe plaque psoriasis who want to feel more confident in their everyday style.  The winners have traveled to New York City where they will receive a one-on-one consultation with Tim Gunn, mentor to the designers on TV’s "Project Runway" and chief creative officer of Liz Claiborne, Inc. Gunn will help the winners embrace their personal style and work with them to select outfits that complement their individual looks and lifestyles, and that work with... Amgen News Service news http://www.medworm.com/rss/comments.php?id=3800913 Tue, 27 Jul 2010 23:00:00 +0100 3800913 http://www.medworm.com/index.php?rid=3792683&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2010_second_quarter_financial_results%2F THOUSAND OAKS, Calif., July 26, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that it plans to report its second quarter financial results on Thursday, July 29, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3792683 Sun, 25 Jul 2010 23:00:00 +0100 3792683 http://www.medworm.com/index.php?rid=3778911&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_appoints_ronald_d_sugar_to_the_companys_board_of_directors%2F THOUSAND OAKS, Calif., July 22, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that its board of directors has appointed Ronald D. Sugar to the company’s board, effective immediately.  Dr. Sugar, 61, is chairman emeritus of Northrop Grumman Corp. and served as the company’s chairman and chief executive officer from 2003 to 2009. He was president and chief operating officer of Northrop from 2001 to 2003. He has been a director of Chevron Corporation since 2005. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3778911 Wed, 21 Jul 2010 23:00:00 +0100 3778911 http://www.medworm.com/index.php?rid=3766121&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_scholars_summer_research_helps_lead_to_science_careers%2F THOUSAND OAKS, Calif. (July 19, 2010) – A Rhodes Scholar, a Labouisse winner, a Hertz Foundation Fellow and co-author of an internationally acclaimed research project – these are just a few examples of what alumni of the Amgen Scholars Program  have achieved. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3766121 Sun, 18 Jul 2010 23:00:00 +0100 3766121 http://www.medworm.com/index.php?rid=3760130&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_grants_priority_review_designation_to_denosumab_biologics_license_appli%2F FDA Accepts Submission Which Includes Data from Three Pivotal Phase 3 Trials THOUSAND OAKS, Calif., July 16, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer. Filed in mid-May with the FDA, the Biologics License Application (BLA) submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three pivotal Phase 3 head-to-head trials versus Zometa(R) (zoledronic acid). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3760130 Thu, 15 Jul 2010 23:00:00 +0100 3760130 http://www.medworm.com/index.php?rid=3756301&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_appoints_jonathan_m_peacock_executive_vice_president_and_chief_financ%2F THOUSAND OAKS, Calif., July 15, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced the appointment effective Sept. 1 of Jonathan M. Peacock as chief financial officer (CFO). He will be responsible for Amgen’s finance and investor relations operations. Peacock will report to Kevin W. Sharer, Amgen’s chairman and chief executive officer, and will succeed Michael A. Kelly, who served as acting CFO since May 2010. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3756301 Wed, 14 Jul 2010 23:00:00 +0100 3756301 http://www.medworm.com/index.php?rid=3756302&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_foundation_and_changemakers_launch_global_online_competition_to_empow%2F THOUSAND OAKS, Calif. and WASHINGTON, July 14, 2010 /PRNewswire via COMTEX/ — The Amgen Foundation is supporting an online competition with Ashoka’s Changemakers to find the best solutions that elevate patients’ voices to improve health outcomes globally. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3756302 Tue, 13 Jul 2010 23:00:00 +0100 3756302 http://www.medworm.com/index.php?rid=3685661&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2F34_teachers_and_schools_across_north_america_receive_10000_amgen_award_for_%2F THOUSAND OAKS, Calif., June 22, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year’s recipients of the 18th annual Amgen Award for Science Teaching Excellence. The award recognizes extraordinary teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the future generation of scientists. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3685661 Mon, 21 Jun 2010 23:00:00 +0100 3685661 http://www.medworm.com/index.php?rid=3664473&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_goldman_sachs_global_healthcare_conference%2F THOUSAND OAKS, Calif., June 15, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 17, 2010 at the Century Plaza Hyatt Regency, Los Angeles, beginning at 9:20 a.m. Pacific Time. Amgen Chairman and CEO Kevin Sharer will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3664473 Mon, 14 Jun 2010 23:00:00 +0100 3664473 http://www.medworm.com/index.php?rid=3664474&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_jeffries_global_life_sciences_conference%2F THOUSAND OAKS, Calif., June 7, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Jeffries Global Life Sciences Conference at 6:00 a.m. Pacific Time on Wednesday, June 9, 2010, at the Grand Hyatt Hotel in New York City. Amgen’s Roy Baynes, vice president of Global Development and Arvind Sood, vice president of Investor Relations will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s website, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3664474 Sun, 06 Jun 2010 23:00:00 +0100 3664474 http://www.medworm.com/index.php?rid=3633042&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnew_amg_386_data_demonstrate_promising_antitumor_activity_in_patients_with_%2F AMG 386 Treatment Response Increased With Dose And Exposure AMG 386 Moving Into Phase 3 For Recurrent Ovarian Cancer Separately, Two Analyses Provide Evidence Of Biomarker As Predictor Of Tumor Response To Motesanib THOUSAND OAKS, Calif., June 6, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.  The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. (Abstract Number: 5000) (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3633042 Sat, 05 Jun 2010 23:00:00 +0100 3633042 http://www.medworm.com/index.php?rid=3633045&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnew_analyses_of_denosumab_pivotal_phase_3_trials_reinforce_potential_advant%2F Integrated Analysis Shows Denosumab Superiority Over Zometa(R) In Delaying Or Preventing Skeletal Related Events In Broad Population With Advanced Cancer Additional Analyses Demonstrate Denosumab Significantly Delays Onset And Worsening Of Bone Pain Over Zometa Exploratory Analysis Shows Denosumab Superior To Zometa In Delaying Time To First Skeletal Related Event Or Hypercalcemia Of Malignancy THOUSAND OAKS, Calif., June 5, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa(R) (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma (&quot... Amgen News Service news http://www.medworm.com/rss/comments.php?id=3633045 Fri, 04 Jun 2010 23:00:00 +0100 3633045 http://www.medworm.com/index.php?rid=3633044&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_demonstrated_superiority_over_zometar_in_delay_of_complications_d%2F The Third Of Three Pivotal Head-To-Head Trials Submitted To FDA For Treatment Of Patients With Bone Metastases THOUSAND OAKS, Calif., June 5, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa(R) (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab’s superiority over Zometa in delaying or preventing skeletal related events (SREs). These statistically significant results will be presented in an oral session on June 6, 2010 at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago (Late Breaking Abstract Number #L... Amgen News Service news http://www.medworm.com/rss/comments.php?id=3633044 Fri, 04 Jun 2010 23:00:00 +0100 3633044 http://www.medworm.com/index.php?rid=3633043&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fstriking_the_balance_community_experts_come_together_for_high_level_dialogu%2F Advocacy Leaders, Renowned Physicians, and Actor Patrick Dempsey Spur Dialogue and Inspire Action in First-of-Its-Kind Roundtable Event CHICAGO , June 5 /PRNewswire/—Eminent leaders and thinkers in the cancer community came together yesterday at the 2010 American Society of Clinical Oncology (ASCO) annual meeting for a first-of-its-kind roundtable event. The session, sponsored by Amgen and its Breakaway from Cancer (R) initiative, was designed to highlight potential areas for improvement throughout the spectrum of cancer care, and inspire action by establishing several calls-to-action for the cancer community and health policymakers. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3633043 Fri, 04 Jun 2010 23:00:00 +0100 3633043 http://www.medworm.com/index.php?rid=3631315&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnew_amg_479_phase_2_data_show_antitumor_activity_in_patients_with_metastati%2F Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. (Abstract Number: 4035) (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3631315 Thu, 03 Jun 2010 23:00:00 +0100 3631315 http://www.medworm.com/index.php?rid=3619923&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_approves_amgens_prolia_denosumab_for_treatment_of_postmenopausal_women_%2F Given As An Injection Every Six Months, Prolia Reduced Risk Of Fracture At The Spine, Hip And Other Sites THOUSAND OAKS, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Amgen Inc.  (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3619923 Mon, 31 May 2010 23:00:00 +0100 3619923 http://www.medworm.com/index.php?rid=3609092&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fprolia_denosumab_granted_marketing_authorization_in_the_european_union%2F Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures First and Only Approved Treatment in Europe for Bone Loss Due to Hormone Ablation in Men with Prostate Cancer First Prolia® Regulatory Approval THOUSAND OAKS, Calif., May 28, 2010 /PRNewswire via COMTEX/ --Amgen Inc.  (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorization for Prolia(R) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. Prolia has been approved in all 27 European Unio... Amgen News Service news http://www.medworm.com/rss/comments.php?id=3609092 Thu, 27 May 2010 23:00:00 +0100 3609092 http://www.medworm.com/index.php?rid=3583769&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_key_clinical_data_to_be_presented_at_american_society_of_c%2F THOUSAND OAKS, Calif., May 20, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company’s oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4- 8, 2010 in Chicago. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3583769 Wed, 19 May 2010 23:00:00 +0100 3583769 http://www.medworm.com/index.php?rid=3575550&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_submits_denosumab_biologics_license_application_to_fda_for_the_reduct%2F THOUSAND OAKS, Calif., May 14, 2010 /PRNewswire via COMTEX/ --Amgen Inc.  (Nasdaq: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials versus Zometa(R) (zoledronic acid). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3575550 Thu, 13 May 2010 23:00:00 +0100 3575550 http://www.medworm.com/index.php?rid=3558620&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_voting_results_of_annual_meeting_of_stockholders1%2F THOUSAND OAKS, Calif., May 12, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN), today announced results of voting at the company’s Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif. Approximately 85 percent of outstanding shares were represented at the meeting. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3558620 Tue, 11 May 2010 23:00:00 +0100 3558620 http://www.medworm.com/index.php?rid=3554462&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_breakaway_from_cancer_to_honor_cancer_survivors_at_amgen_tour_of_cal%2F THOUSAND OAKS, Calif. – (May 11, 2010) – Amgen today announced that four inspirational cancer survivors who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer® Champions to participate in Breakaway Miles during the 2010 Amgen Tour of California. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3554462 Mon, 10 May 2010 23:00:00 +0100 3554462 http://www.medworm.com/index.php?rid=3540748&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_scientists_visit_biotechnology_classrooms_across_the_country_in_suppo%2F THOUSAND OAKS, Calif., May 6, 2010 /PRNewswire via COMTEX/ --Answering the call from President Obama to reinvigorate science and math education by connecting students to hands-on learning experiences, Amgen scientists will visit high schools that include the Amgen-Bruce Wallace Biotechnology Lab Program in their science curriculum. In conjunction with National Lab Day, the visits will give students a first-hand perspective on how the very same lab tools and techniques used in the program apply to creating biotechnology therapeutics. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3540748 Wed, 05 May 2010 23:00:00 +0100 3540748 http://www.medworm.com/index.php?rid=3521620&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_deutsche_bank_35th_annual_healthcare_conference%2F THOUSAND OAKS, Calif., April 29, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Deutsche Bank 35th Annual Healthcare Conference on Tuesday, May 4, 2010 at the InterContinental, Boston, Mass., beginning at 9:20 a.m. Eastern Time. Senior Vice President of North America Commercial Operations Jim Daly will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s website, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3521620 Wed, 28 Apr 2010 23:00:00 +0100 3521620 http://www.medworm.com/index.php?rid=3506673&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_appoints_robert_a_bradway_president_and_chief_operating_officer%2F THOUSAND OAKS, Calif., April 26, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that the Board of Directors has appointed Robert A. Bradway president and chief operating officer (COO), effective May 11. In this new role, Bradway will report to Kevin Sharer, Amgen’s chairman and chief executive officer, and will be responsible for the company’s Global Commercial Operations, Manufacturing Operations, Strategy & Corporate Development, Information Technology, Global Government Affairs and Compliance. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3506673 Sun, 25 Apr 2010 23:00:00 +0100 3506673 http://www.medworm.com/index.php?rid=3492612&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_first_quarter_2010_adjusted_earnings_per_share_increased_20_percent_%2F THOUSAND OAKS, Calif., April 21, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.30 for the first quarter of 2010, an increase of 20 percent compared to $1.08 for the first quarter of 2009. Adjusted net income increased 14 percent to $1,282 million for the first quarter of 2010 compared to $1,120 million for the first quarter of 2009. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3492612 Tue, 20 Apr 2010 23:00:00 +0100 3492612 http://www.medworm.com/index.php?rid=3492614&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_preclinical_study_demonstrated_anti_tumor_activity_in_mammary_tumor_m%2F THOUSAND OAKS, Calif., April 19, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3492614 Sun, 18 Apr 2010 23:00:00 +0100 3492614 http://www.medworm.com/index.php?rid=3492613&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2010_first_quarter_financial_results%2F THOUSAND OAKS, Calif., April 19, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it plans to report its first quarter financial results on Wednesday, April 21, 2010 after the close of the U.S.  financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3492613 Sun, 18 Apr 2010 23:00:00 +0100 3492613 http://www.medworm.com/index.php?rid=3485201&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fanalysis_of_vectibixr_study_using_new_gene_technology_helps_to_advance_pros%2F THOUSAND OAKS, Calif., April 18, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a new biomarker analysis of the pivotal Phase 3 “408” trial of Vectibix(R) (panitumumab) plus best supportive care (BSC) compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer (mCRC). Highlighted results were presented at the opening press conference at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3485201 Sat, 17 Apr 2010 23:00:00 +0100 3485201 http://www.medworm.com/index.php?rid=3462107&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_biomarker_and_preclinical_data_to_be_presented_at_american%2F THOUSAND OAKS, Calif., April 12, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents and a comprehensive biomarker analysis will be presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C. from April 17 - 21, 2010. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3462107 Sun, 11 Apr 2010 23:00:00 +0100 3462107 http://www.medworm.com/index.php?rid=3401584&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_cowen_and_company_30th_annual_healthcare_conference%2F THOUSAND OAKS, Calif., March 8, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) will present at the Cowen and Company 30th Annual Healthcare Conference on Wednesday, March 10, 2010 at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:30 a.m. Eastern Time. James Daly, Amgen’s Senior Vice President of North American Commercial Operations, will present.  Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3401584 Mon, 08 Mar 2010 00:00:00 +0100 3401584 http://www.medworm.com/index.php?rid=3401585&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fproject_runways_tim_gunn_returns_to_address_psoriasistm_and_empower_patient%2F NEW YORK, March 3, 2010 /PRNewswire via COMTEX/—Amgen and Pfizer have once again partnered with Tim Gunn, television host, fashion consultant and chief creative officer of Liz Claiborne, Inc., to launch the second year of Addressing Psoriasis™, the disease awareness program designed to help people with psoriasis get more information about their condition and feel more confident in their everyday style. Dermatologist Susan C. Taylor, M.D., and Gunn are working together, again in 2010, to encourage people with psoriasis to visit a dermatologist and take the first step in managing their condition. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3401585 Wed, 03 Mar 2010 00:00:00 +0100 3401585 http://www.medworm.com/index.php?rid=3289798&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Ffda_classifies_proliatm_denosumab_complete_response_submission_and_targets_%2F THOUSAND OAKS, Calif., Feb 19, 2010 /PRNewswire via COMTEX/—Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company’s Complete Response submission for Prolia(TM) (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3289798 Fri, 19 Feb 2010 00:00:00 +0100 3289798 http://www.medworm.com/index.php?rid=3289799&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_and_centocor_ortho_biotech_products_finalize_esa_risk_evaluation_and_%2F THOUSAND OAKS, Calif., Feb 16, 2010 /PRNewswire via COMTEX/—Amgen Inc.  (Nasdaq: AMGN) and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa) and PROCRIT(R) (Epoetin alfa). The FDA has determined that a REMS is necessary for ESAs to ensure the benefits of these drugs outweigh the risks of shortened overall survival and/or increased tumor progression or recurrence as identified in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid and cervical cancers. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3289799 Tue, 16 Feb 2010 00:00:00 +0100 3289799 http://www.medworm.com/index.php?rid=3257065&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_study_published_in_the_lancet_oncology_demonstrated_86_percent_tu%2F THOUSAND OAKS, Calif. (February 9, 2010) – Amgen (NASDAQ: AMGN) issued the following statement on the publication of results online today by the Lancet Oncology. For a summary of the manuscript click here. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3257065 Tue, 09 Feb 2010 00:00:00 +0100 3257065 http://www.medworm.com/index.php?rid=3261141&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_demonstrated_superiority_over_zometar_in_pivotal_phase_3_head_to_%2F THOUSAND OAKS, Calif., Feb 08, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints. Denosumab demonstrated superiority over Zometa for both delaying the time to the first on-study skeletal related event (SRE) (fracture, radiation to bone, surgery to bone or spinal cord compression) (hazard ratio 0.82, 95 percent CI: 0.71, 0.95), and reducing the rate of multiple SREs (hazard ratio 0.82, 95 percent CI: 0.71, 0.94). Both results were statistically significant. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3261141 Mon, 08 Feb 2010 00:00:00 +0100 3261141 http://www.medworm.com/index.php?rid=3261142&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_fourth_quarter_2009_adjusted_earnings_per_share_decreased_1_percent_%2F THOUSAND OAKS, Calif., Jan 25, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.05 for the fourth quarter of 2009, a decrease of 1 percent compared to $1.06 for the fourth quarter of 2008. Adjusted net income decreased 5 percent to $1,065 million in the fourth quarter of 2009 compared to $1,124 million in the fourth quarter of 2008. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3261142 Mon, 25 Jan 2010 00:00:00 +0100 3261142 http://www.medworm.com/index.php?rid=3261143&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_presents_complete_results_from_two_pivotal_phase_3_studies_of_vectibi%2F THOUSAND OAKS, Calif., Jan 21, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix(R) (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME ‘203’ and ‘181’ trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3261143 Thu, 21 Jan 2010 00:00:00 +0100 3261143 http://www.medworm.com/index.php?rid=3261144&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2009_fourth_quarter_and_full_year_financial_resu%2F THOUSAND OAKS, Calif., Jan 20, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3261144 Wed, 20 Jan 2010 00:00:00 +0100 3261144 http://www.medworm.com/index.php?rid=3261145&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_donates_2_million_establishes_earthquake_relief_program%2F THOUSAND OAKS, Calif., Jan 14, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq:  AMGN) today announced that the company will donate $2 million to Haiti relief efforts. Amgen staff are being encouraged to be generous and that effort should also generate meaningful additional support. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3261145 Thu, 14 Jan 2010 00:00:00 +0100 3261145 http://www.medworm.com/index.php?rid=3098734&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_receives_chmp_positive_opinion_for_proliatm_denosumab_in_the_european%2F THOUSAND OAKS, Calif. – Dec 18, 2009 – Amgen Inc. (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. If approved by the European Commission, Amgen would receive marketing authorization for Prolia in all European Union (EU) Member States. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3098734 Fri, 18 Dec 2009 00:00:00 +0100 3098734 http://www.medworm.com/index.php?rid=3094713&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_issues_statement_on_update_to_us_prescribing_information_for_erythrop%2F On December 16, 2009, Amgen updated the boxed warning in the labeling information for the class of drugs known as erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), to reflect an increased risk of stroke when ESAs are administered to chronic renal failure patients to target hemoglobin levels of 13 g/dL and above. The update was made based on results from the recently completed clinical study, TREAT (the Trial to Reduce Cardiovascular Events with Aranesp Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. In addition, the Warnings section has been updated to include a description of TREAT and t... Amgen News Service news http://www.medworm.com/rss/comments.php?id=3094713 Wed, 16 Dec 2009 00:00:00 +0100 3094713 http://www.medworm.com/index.php?rid=3054831&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fnew_amgen_scholars_web_site_launches_to_build_a_global_network_for_future_s%2F THOUSAND OAKS, Calif. (Dec. 3, 2009) – Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world’s leading universities.  Now, the Amgen Scholars – past, present and future – will have exclusive access to the online Amgen Scholars Community at www.amgenscholars.com. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3054831 Thu, 03 Dec 2009 00:00:00 +0100 3054831 http://www.medworm.com/index.php?rid=3054832&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_highlights_data_to_be_presented_at_ash%2F THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/—Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate?? (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3054832 Mon, 30 Nov 2009 00:00:00 +0100 3054832 http://www.medworm.com/index.php?rid=3021379&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_recognized_for_best_pipeline_and_best_new_drug_at_scrip_awards%2F THOUSAND OAKS, Calif., Nov. 23—Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a Nov. 18 ceremony in London. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3021379 Mon, 23 Nov 2009 00:00:00 +0100 3021379 http://www.medworm.com/index.php?rid=3006415&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_lazard_capital_healthcare_conference%2F THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3006415 Mon, 16 Nov 2009 00:00:00 +0100 3006415 http://www.medworm.com/index.php?rid=3006416&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_18th_annual_credit_suisse_healthcare_conference%2F THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3006416 Thu, 12 Nov 2009 00:00:00 +0100 3006416 http://www.medworm.com/index.php?rid=3006417&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_overall_survival_results_for_vectibixr_in_first_line_metast%2F THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.  Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3006417 Thu, 05 Nov 2009 00:00:00 +0100 3006417 http://www.medworm.com/index.php?rid=3006418&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fcall_for_applications_the_amgen_award_for_science_teaching_excellence1%2F THOUSAND OAKS, Calif., Nov. 4 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE).  This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in communities where Amgen operates. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3006418 Wed, 04 Nov 2009 00:00:00 +0100 3006418 http://www.medworm.com/index.php?rid=3006419&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Flarge_study_of_anemia_treatment_in_chronic_kidney_disease_patients_not_on_d%2F THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes. The study, published online today in the New England Journal of Medicine and presented at the annual meeting of the American Society of Nephrology (ASN), failed to meet its primary objectives of demonstrating a reduction in all-cause mortality, cardiovascular morbidity, including heart failure, heart attack, stroke, or hospitalization for myocardial ischemia, or end-stage renal disease (ESRD). (Source: Amgen News Service... Amgen News Service news http://www.medworm.com/rss/comments.php?id=3006419 Fri, 30 Oct 2009 00:00:00 +0100 3006419 http://www.medworm.com/index.php?rid=3006420&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgens_third_quarter_2009_adjusted_earnings_per_share_increased_21_percent_%2F THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=3006420 Wed, 21 Oct 2009 00:00:00 +0100 3006420 http://www.medworm.com/index.php?rid=2903943&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_provides_update_on_status_of_proliatm_denosumab_biologics_license_app%2F THOUSAND OAKS, Calif. – Oct 19, 2009 – Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis. The FDA issues Complete Response Letters to request additional information needed to complete the review of applications for product approval.  (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=2903943 Sun, 18 Oct 2009 23:00:00 +0100 2903943 http://www.medworm.com/index.php?rid=2897148&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_announces_webcast_of_2009_third_quarter_financial_results%2F THOUSAND OAKS, Calif. – Oct. 15 – Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Wednesday, Oct. 21, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=2897148 Wed, 14 Oct 2009 23:00:00 +0100 2897148 http://www.medworm.com/index.php?rid=2826777&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fvectibixr_in_combination_with_chemotherapy_significantly_improves_progressi%2F THOUSAND OAKS, Calif. – Sept 24, 2009 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘203’ trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard ratio 0.80; p=0.02)) in patients with KRAS wild-type mCRC (primary endpoint). The results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 10LBA). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=2826777 Wed, 23 Sep 2009 23:00:00 +0100 2826777 http://www.medworm.com/index.php?rid=2817498&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fvectibixr_in_combination_with_chemotherapy_significantly_improves_progressi%2F THOUSAND OAKS, Calif. – Sept. 22 – Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 ‘181’ trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 14LBA). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=2817498 Mon, 21 Sep 2009 23:00:00 +0100 2817498 http://www.medworm.com/index.php?rid=2817497&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fdenosumab_demonstrates_superiority_over_zometar_in_delay_of_complications_d%2F THOUSAND OAKS, Calif. – Sept. 22 – Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 2LBA). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=2817497 Mon, 21 Sep 2009 23:00:00 +0100 2817497 http://www.medworm.com/index.php?rid=2813673&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Fphase_3_trial_shows_denosumab_delayed_skeletal_related_events_in_advanced_c%2F THOUSAND OAKS, Calif. – Sept. 21 – Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA). (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=2813673 Sun, 20 Sep 2009 23:00:00 +0100 2813673 http://www.medworm.com/index.php?rid=2813674&cid=s_37942_34_f&fid=37942&url=http%3A%2F%2Fwww.amgennews.com%2Findex.php%2F2008NewsService%2Famgen_to_present_at_the_ubs_global_life_sciences_conference%2F THOUSAND OAKS, Calif. – Sept. 17 – Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Monday, Sept. 21, 2009, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. (Source: Amgen News Service) Amgen News Service news http://www.medworm.com/rss/comments.php?id=2813674 Wed, 16 Sep 2009 23:00:00 +0100 2813674